Cue Biopharma, Inc.
Cue Biopharma, Inc. Q2 FY2023 earnings call
August 9, 2023 · fiscal period ended 2023-06
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2023-08-09
Management highlights
Dan introduces the call agenda. Anish discusses the Immuno-STAT platform's design, clinical trial results, and platform modularity. Matteo provides updates on CUE-101 and 102 clinical trials, including response rates, survival data, and combination therapy results. Anish talks about the pipeline and platform versatility. Kerri provides financials for Q2 2023, noting cash position and funding through Q3 2024.
Segment performance
No traditional product segment financial performance detailed. Focus is on the Immuno-STAT platform and clinical trials.
Guidance
Kerri states the company's cash position of approximately $57.9 million as of June 30, 2023, which is expected to fund operations through Q3 2024. Forward-looking on pipeline developments, including continued clinical trial progress for CUE-101, 102, and preclinical pipeline, as well as strategic discussions for the oncology pipeline.
Q&A highlights
Q: Ted Tenthoff from Piper Sandler asks about the process of generating more data and strategic/financial factors moving forward.
A: Dan Passeri mentions strategic corporate development initiatives, FDA meetings to define registration paths, and considering various scenarios for CUE-101 and 102.
Q: Ren Benjamin from JMP Securities asks about additional information needed for regulatory discussions, neoadjuvant study status, and CUE-102 program.
A: Matteo Levisetti explains plans for a registrational trial, neoadjuvant trial progress, and CUE-102 enrollment dynamics and data disclosure plans.
Q: Unidentified Analyst from Stifel asks about targeting specific populations for CUE-101 plus pembrolizumab and CUE-102 enrollment details.
A: Matteo Levisetti responds that all CPS score patients benefit from the combination, CUE-102 enrollment is fast due to unmet need, and initial data on CUE-102 will be presented at SITC.
Q: Trevor from Oppenheimer asks about additional data expected in 2024.
A: Dan Passeri mentions FDA discussions, strategic decisions on indications, and data from CUE-102 dose escalation to be presented at SITC.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | — | — | — |
| Revenue | — | — | — | — |
Transcript
August 9, 2023Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.